LifeCare Partners and LSP lead CHF 15m round for Kuros

Existing backers VI Partners and The Swiss Helvetia Fund also took part in the financing round, alongside US firm Omega Funds and a variety of European family offices.

The fresh capital will fund the company’s commercial launch of tissue sealant KUR-023, used in cranial and spinal surgery. It will also finance phase-III clinical studies for its KUR-111 product, which is used in the treatment of spinal injuries.

Following a year of particularly high dealflow, institutional investments in the Swiss biotech sector have dropped off in 2015, according to unquote” data. Most recently, Redalpine led a CHF 2.3m funding round for Memo Therapeutics in July, marking only the second investment in the segment this year.

Company
Headquartered in Zurich, Kuros develops biomaterials used for wound healing, tissue sealant and orthobiologics. The company was founded in 2000 in a spin-off from the Swiss Federal Institute of Technology and University of Zurich.

People
LifeCare managing partner Gerhard Ries, Endeavour Vision operating partner Dominik Ellenrieder and LSP partner Jörg Neermann will take seats on the board at Kuros. Didier Cowling is CEO of Kuros.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Switzerland